Last updated on February 2019

A Study to Provide Complementary Efficacy Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting


Brief description of study

This national, open-label study is designed to give complementary efficacy, safety and patient reported outcomes (PROs) data in participants with active relapsing forms of MS. Participants will receive a maximum of 2 treatment cycles of ocrelizumab infusions: an initial dose of two 300 milligram (mg) infusions separated by 14 days followed by one single infusion of 600 mg ocrelizumab 24 weeks after the first infusion. Disease activity is determined by clinical relapses and/or Magnetic Resonance Imaging (MRI) activity.

Clinical Study Identifier: NCT03589105

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: ML40359 ...

CH de Gonesse; Neurologie
Gonesse, France
3.32miles
  Connect »

Reference Study ID Number: ML40359 ...

Fondation Rothschild; Service de Neurologie
Paris, France
7.38miles
  Connect »

Reference Study ID Number: ML40359 ...

Hopital Saint Antoine; Neurologie
Paris, France
9.8miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.